XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
 3 Months Ended 6 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
OPERATING EXPENSES        
Research and development $ 4,480,863 $ 7,649,459 $ 9,825,113 $ 13,669,218
Financing costs (Note 7) 1,944 3,526 4,294 7,851
General and administration 3,730,692 3,817,370 6,249,811 6,879,540
Total operating expenses (8,213,499) (11,470,355) (16,079,218) (20,556,609)
Foreign exchange (762) 16,259 10,771 29,428
Interest and other income 1,155,622 481,751 2,267,926 556,335
Derivative liability gain   117,741 0 18,423
Loss for the period before taxes (7,058,639) (10,854,604) (13,800,521) (19,952,423)
Income tax expense (1,600)   (1,600) (100)
Net loss for the period (7,060,239) (10,854,604) (13,802,121) (19,952,523)
OTHER COMPREHENSIVE LOSS        
Unrealized loss on short-term investments (Note 4) (59,115) (48,731) (29,688) (48,731)
Loss and comprehensive loss for the period $ (7,119,354) $ (10,903,335) $ (13,831,809) $ (20,001,254)
Earnings Per Share [Abstract]        
Basic loss per common share $ (0.16) $ (0.25) $ (0.31) $ (0.45)
Diluted loss per common share $ (0.16) $ (0.25) $ (0.31) $ (0.45)
Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]        
Weighted average number of common shares outstanding - Basic 44,092,374 44,030,480 44,082,725 44,009,903
Weighted average number of common shares outstanding -Diluted 44,092,374 44,030,480 44,082,725 44,009,903